Investor Presentaiton
Investor Presentation
First six months of 2018
Slide 84
SaxendaⓇ has rapidly grown value market share, but market
development efforts are required to expand the market
Despite strong SaxendaⓇ growth, US obesity care
market remains small at around USD 787 million
Generic AOM
Novo Nordisk is investing in overcoming the
barriers preventing effective obesity care
Mindset
SaxendaⓇ
Other branded AOM
TRX SU market share
mUSD/value market share
100
800
7%
90
700
80
600
41%
70
500
60
83%
50
400
Few
prescribers
engaged
40
300
30
200
53%
20
100
Limited
patient
10
14%
0
3%
Volume
Value
Current state
Acute weight loss focus
with SaxendaⓇ stay-
time ~5 months
Key initiatives
Advocate for chronic
treatment through
partnerships
access
Less than 3,000
physicians write ≥10
AOM prescriptions per
month
Only 2 in 5 of ~95
million adults with
obesity have access to
reimbursed medication
Launch obesity
educator programme
Obtain Medicare
coverage
through support of
"Treat and Reduce
Obesity Act"
AOM: Anti-obesity medication; TRX SU Volume
Source: IQVIA NPA moving annual total through June 2018; NSP moving annual total through May 2018
changing
diabetes®
novo nordiskView entire presentation